Tofacitinib is an oral Janus kinase inhibitor that blocks effects of proinflammatory cytokines. Tofacitinib is approved for treatment of patients with moderately severe or severe active rheumatoid arthritis in patients who did not respond to treatment with disease modifying anti-rheumatic drugs (DMARD) and/or biologic agents. Tofacitinib can be used for monotherapy or in combination with metothrexate or other DMARDs. An article discusses the clinical cases showing efficacy and safety of tofacitinib in different clinical situations.
Rheumatoid arthritis, treatment, tofacitinib, Janus kinase inhibitor.